Table 1. Demographic information for patients receiving nadunolimab as monotherapy.

	IL1RAP high (n=5)	IL1RAP low (n=10)
Age (years); mean (range)	63 (61–64)	62 (40–81)
Sex (female/male); n (%)	2 (40%) / 3 (60%)	2 (20%) / 8 (80%)
ECOG 0/1; n (%)	3 (60%) / 2 (40%)	3 (30%) / 7 (70%)
Location of metastases at study entry; n (%)
Liver	3 (60%)	9 (90%)
Lymph node	2 (40%)	3 (30%)
Other sites	3 (60%)	6 (60%)
No of previous lines of treatment
1	3 (60%)	4 (40%)
2	1 (20%)	4 (40%)
≥3	1 (20%)	2 (20%)

ECOG, Eastern Cooperative Oncology Group